Methylphenidate Inhibits the Development of Myopia by Altering Dopamine and Norepinephrine Reuptake
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.12.52 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Cindy Karouta and 4 co-authors. Institution: Biomedical Science, Faculty of Science and Technology, University of Canberra, Bruce, Canberra, Australian Capital Territory, Australia. Major MEDLINE topics: Myopia, Dopamine, Methylphenidate, Norepinephrine. Cited 7 times so far (Crossref); 146 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
Dopaminergic dysregulation plays a critical role in myopia development in animal models. Although its relevance to human myopia remains uncertain, the observation that methylphenidate hydrochloride (MPH)-a dopamine (DA) and norepinephrine (NE) uptake inhibitor-slows myopia progression in children suggests a possible link. This study aimed to investigate whether MPH can inhibit myopic growth and elucidate the underlying mechanisms using an animal model.
Methods
MPH was administered via oral, topical, or intravitreal routes for 7 days (minimum 5 per group) to chicks undergoing form-deprivation myopia (FDM). Myopia was assessed by refraction and axial length. Retinal DA and NE dynamics-including synthesis, release, uptake, breakdown (DA only), extracellular levels, and receptor sensitivity-were evaluated using mass spectrometry and chronoamperometry (minimum 5 per group). DA and NE receptors were pharmacologically blocked (DA = spiperone, SCH-23390; and NE = yohimbine) to determine their role in MPH's anti-myopic effects.
Results
MPH inhibited FDM via all administration routes (oral = 55%, P < 0.05, topical = 45%, P < 0.05, and intravitreal = 87%, P < 0.05 protection against myopic growth). It enhanced DA and NE synthesis while blocking their uptake, resulting in elevated extracellular levels. MPH's anti-myopic effects were abolished when DA or NE receptors were pharmacologically blocked. Additionally, NE receptor stimulation alone inhibited FDM (P < 0.05).
Conclusions
MPH suppresses experimental myopia, with its effects linked to increased extracellular levels of DA and NE. These findings align with the anti-myopic effects observed in clinical studies, supporting a role for DA in human myopia and suggesting that NE may also contribute to the regulation of ocular growth.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Biomedical Science, Faculty of Science and Technology, University of Canberra, Bruce, Canberra, Australian Capital Territory, Australia.
- Research School of Biology, Australian National University, Australian Capital Territory, Australia.
- John Curtin School of Medical Research, The Australian National University, Australian Capital Territory, Australia.
Cite
APA
Karouta, C., Thomson, K., Morgan, I., Booth, L., & Ashby, R. (2025). Methylphenidate Inhibits the Development of Myopia by Altering Dopamine and Norepinephrine Reuptake. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.12.52
Vancouver
Karouta C, Thomson K, Morgan I, Booth L, Ashby R. Methylphenidate Inhibits the Development of Myopia by Altering Dopamine and Norepinephrine Reuptake. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.12.52
BibTeX
@article{Karouta2025,
author = {Karouta, Cindy and Thomson, Kate and Morgan, Ian and Booth, Lauren and Ashby, Regan},
title = {Methylphenidate Inhibits the Development of Myopia by Altering Dopamine and Norepinephrine Reuptake},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.12.52}
}
EUVIMED